Intensive blood pressure control reduced the composite of CVD death, nonfatal MI, nonfatal stroke, revascularization, and heart failure (HR 0.79; 95% CI 0.65-0.96; P=0.02).
Cohort
Does intensive blood pressure control reduce cardiovascular outcomes in patients with type 2 diabetes mellitus and additional cardiovascular risk factors?
Intensive blood pressure control significantly reduces cardiovascular outcomes in patients with type 2 diabetes and additional cardiovascular risk factors, though with an increase in treatment-related adverse events.
Effect estimate: HR 0.79 (95% CI 0.65-0.96)
p-value: p=0.02
OBJECTIVE We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS This study was a post hoc, multivariate, subgroup analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants. Participants were eligible for the analysis if they were in the standard glucose control arm of ACCORD-BP and also had the additional CVD risk factors required for SPRINT (Systolic Blood Pressure Intervention Trial) eligibility. We used a Cox proportional hazards regression model to compare the effect of intensive versus standard BP control on CVD outcomes. The “SPRINT-eligible” ACCORD-BP participants were pooled with SPRINT participants to determine whether the effects of intensive BP control interacted with T2DM. RESULTS The mean baseline Framingham 10-year CVD risk scores were 14.5% and 14.8%, respectively, in the intensive and standard BP control groups. The mean achieved systolic BP values were 120 and 134 mmHg in the intensive and standard BP control groups (P 0.001). Intensive BP control reduced the composite of CVD death, nonfatal myocardial infarction (MI), nonfatal stroke, any revascularization, and heart failure (hazard ratio 0.79; 95% CI 0.65–0.96; P = 0.02). Intensive BP control also reduced CVD death, nonfatal MI, and nonfatal stroke (hazard ratio 0.69; 95% CI 0.51–0.93; P = 0.01). Treatment-related adverse events occurred more frequently in participants receiving intensive BP control (4.1% vs. 2.1%; P = 0.003). The effect of intensive BP control on CVD outcomes did not differ between patients with and without T2DM (P 0.62). CONCLUSIONS Intensive BP control reduced CVD outcomes in a cohort of participants with T2DM and additional CVD risk factors.
Buckley et al. (Mon,) conducted a cohort in Type 2 diabetes mellitus with additional cardiovascular risk factors. Intensive blood pressure control vs. Standard blood pressure control was evaluated on Composite of CVD death, nonfatal myocardial infarction (MI), nonfatal stroke, any revascularization, and heart failure (HR 0.79, 95% CI 0.65-0.96, p=0.02). Intensive blood pressure control reduced the composite of CVD death, nonfatal MI, nonfatal stroke, revascularization, and heart failure (HR 0.79; 95% CI 0.65-0.96; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: